Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with...

TBPH : 29.89 (+3.50%)
INVA : 13.06 (+0.69%)
JNJ : 138.00 (-0.63%)
GSK : 35.06 (-0.37%)
US Anticoagulation Therapy Market to 2022 - Major Players are C. H. Boehringer Sohn, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Daiichi Sankyo and Portola Pharmaceuticals

The "US Anticoagulation Therapy Market - Forecast to 2022" report has been added to Research and Markets' offering.

JNJ : 138.00 (-0.63%)
PTLA : 49.28 (+0.26%)
BMY : 61.32 (-0.89%)
Hip Replacement Lawsuit News: DePuy Pinnacle Plaintiffs Awarded $247 Million At Conclusion of 4th Federal Bellwether Trial, Bernstein Liebhard LLP Reports

Johnson & Johnson and its DePuy Orthopaedics subsidiary have been ordered to pay $247 million to six plaintiffs who experienced the premature failure of a metal-on-metal version of the companies' Pinnacle...

JNJ : 138.00 (-0.63%)
Federal Jury Returns $247 Million Verdict in Defective Hip Implants Case

A federal court jury in Texas returned a $247 million verdict on behalf of six people who suffered serious medical complications caused by the defective metal-on-metal hip implants made by Johnson & Johnson...

JNJ : 138.00 (-0.63%)
Federal Jury Returns $247 Million Verdict in Defective Hip Implants Case

DALLAS , Nov. 16, 2017 /PRNewswire/ -- A federal court jury in Texas returned a $247 million verdict on behalf of six people who suffered serious medical complications caused by the defective...

JNJ : 138.00 (-0.63%)
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)
LLY : 82.89 (-0.66%)
PFE : 35.37 (-0.53%)
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

BAYRY : 31.7900 (-0.05%)
AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
LLY : 82.89 (-0.66%)
PCRX : 40.25 (+1.90%)
BMY : 61.32 (-0.89%)
Achillion Announces Pricing of Secondary Offering Of Common Stock

Achillion Pharmaceuticals, Inc. ("Achillion") (NASDAQ:ACHN) today announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson...

ACHN : 3.43 (-3.65%)
JNJ : 138.00 (-0.63%)
MacroGenics Names Dr. Jay Siegel to its Board of Directors

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well...

MGNX : 19.20 (+5.61%)
JNJ : 138.00 (-0.63%)
J&J Presents Positive New Data for Diabetes Drug Invokana

Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.

NVO : 50.91 (+0.81%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
LLY : 82.89 (-0.66%)
Achillion (ACHN) Shares Down as J&J Announces Stake Sale

Achillion's (ACHN) shares fell following the announcement that J&J will sell its complete stake in the company.

SCMP : 10.55 (+1.93%)
ACHN : 3.43 (-3.65%)
JNJ : 138.00 (-0.63%)
ALXN : 110.87 (+0.49%)
Featured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics

Research Desk Line-up: Intrexon Post Earnings Coverage

XON : 12.85 (-5.65%)
JNJ : 138.00 (-0.63%)
ZYME : 7.60 (-7.77%)
Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.

AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)
AGN : 174.88 (+0.04%)
ALKS : 48.40 (+1.36%)
Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis

CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.

LGND : 140.31 (-0.99%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
PFE : 35.37 (-0.53%)
Blood Pressure Control Achieved With Fewer Or No Medications Within One Month Of Bariatric Surgery And Maintained Over 12 Months

Bariatric surgery may reduce or eliminate the need for high blood pressure medications in patients with obesity, often within one month, according to the GATEWAY* Study, the first randomized clinical trial...

JNJ : 138.00 (-0.63%)
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.

LGND : 140.31 (-0.99%)
PDLI : 2.84 (-0.35%)
AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)
Fretting Over Tax Plan Uncertainty? Buy 5 Ultra-Safe Stocks

With the markets apprehending a healthy pullback after a strong run, investing in stocks that are immune to market gyrations seems judicious. The best way to go about doing this is by creating a portfolio...

GOOGL : 1,035.89 (-1.20%)
AAPL : 170.15 (-0.56%)
DLTR : 94.61 (-0.02%)
V : 109.82 (-1.08%)
JNJ : 138.00 (-0.63%)
EL : 124.69 (-0.76%)
XOM : 80.24 (-0.40%)
AMZN : 1,129.88 (-0.65%)
Johnson & Johnson Innovation Launches Digital Beauty QuickFire Challenge to Tackle some of the Toughest Consumer Skincare Problems

Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., today announced the launch of the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies...

JNJ : 138.00 (-0.63%)
Johnson & Johnson Innovation Launches Digital Beauty QuickFire Challenge to Tackle some of the Toughest Consumer Skincare Problems

Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., today announced the launch of the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies...

JNJ : 138.00 (-0.63%)
Johnson & Johnson Innovation Launches Digital Beauty QuickFire Challenge to Tackle some of the Toughest Consumer Skincare Problems

Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., today announced the launch of the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies...

JNJ : 138.00 (-0.63%)

Van Meerten Stock Picks

My 5 Favorite Small Caps
This morning I wanted to find the 5 Small Cap Stocks that had the best returns over the past year but still appeared to have some more room to climb.
SEDG -0.20 , GDOT +0.11 , CTRL -1.36 , ESIO -0.65 , QNST +0.23
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 -0.06% ) this morning are down 0.06% on concern Special Counsel Mueller's criminal investigation between Trump campaign officials and Russia is deepening. Two people familiar with the matter... Read More

Chart of the Day

Chart of the Day

D R Horton (DHI) is the Barchart Chart of the Day.  The home builder has a Trend Spotter buy signal, a Weighted Alpha of 77.13+ and gained 68.46% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed Friday with most contracts 4 – 6 1/2 cents higher, as Dec came back to only lose a half cent on the week. Pre-weekend profit taking gets some of the credit. The CFTC report on Friday showed the spec funds holding a new recor...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart